Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Dec 4, 2017
Marty Driscoll, CEO of Spring Bank Pharmaceuticals, discusses treatments for the hepatitis B virus, a disease suffered by 250 million people globally who are chronically infected with the hepatitis B virus. Marty talks about what a functional cure for chronically infected patients means, and what Spring Bank is doing to help those affected. Spring Bank is developing a new oral drug named inarigivir that is a selective immunomodulator/encapsidation inhibitor. Inarigivir could become a key component of a future safe and simple combination treatment in an effort to substantially increase functional cure rates for patients with chronic hepatitis B and reduce their need for daily drugs.
@springbankpharm
#HBV #HepatitisB #Functionalcure #inarigivir